BCL2 and nevus: Using an NrasQ61K-transgenic GCMN mouse model, which mimics the common mutation in Chinese GCMN patients, we demonstrated that venetoclax, a BCL2 inhibitor, effectively induces hypopigmentation and clears nevus cells via intralesional injection or oral administration.